The European Lead Factory hold annual meetings intended to support early career scientists, this years meeting will focus on "Hit to Lead optimisation". The meeting will be held at Janssen Pharmaceutica NV, Beerse, Belgium, November 6th - 7th 2017.
Full details are here https://www.europeanleadfactory.eu/early-career-researcher-event/.
Free participation (incl. reimbursement of travel costs up to € 250, accommodation, access to the social get-together) at the conference.
The draft agenda is here.
A great opportunity for those just starting on their drug discovery career.
We are now starting to see some of the results of the screening of academic projects at the European Lead factory that was initiated in 2013.
Dr Mahlapuu’s group, based at the University of Gothenburg, first identified a new target which could be used to reverse metabolic complications in type 2 diabetes. With the help of the European Lead Factory experts, she then screened the Joint European Compound Library of the then 320,000 industry compounds and identified a set of selective and potent small molecules which interfere with this target.
They have now formed a spinout company to develop these leads. ScandiCure has received 1 MSEK from the 2016 SWElife program to continue the development of first-in-class anti-diabetic drug based on small molecule antagonists of a novel key mediator - serine/threonine protein kinase 25 (STK25).
The latest newsletter from the European Lead Factory has just been published and highlights a number of notable achievements.
As a result of the screening campaigns >3000 qualified hits have been awarded to private and public target owners. 72 public target programmes have been accepted, 48 high throughput screens finished and 41 hit lists with associated data reports handed over to the target owners. >150 bespoke assays have been developed in order to extract the most interesting hits for public programmes.
There are now 450,000 compounds in the compound library of which 120,000 are novel compound specifically synthesised for the ELF.
You can read more details here https://www.europeanleadfactory.eu/results/
The European Lead Factory is a collaborative public-private partnership aiming to deliver innovative drug discovery starting points. Having established the first European Compound Library and the first European Screening Centre, the EU Lead Factory aims to give free access to up to 500,000 novel compounds, a unique industry-standard uHTS platform, and much more.
We are now starting to see publications describing these endeavours..